KLTO

Klotho Neurosciences, Inc. Common Stock

KLTO

Market cap $36.2M

Overview Fund Activity

0.5902 USD

-0.0287

4.64%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.5902

0.0000

0%

1 day

-4.64%

5 days

25.68%

1 month

-26.89%

3 months

-70.49%

6 months

101.71%

Year to date

-15.63%

1 year

-20.24%

5 years

-94.03%

10 years

-94.03%

About: Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Employees: 3

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

417% more capital invested

Capital invested by funds: $192K [Q1] → $994K (+$802K) [Q2]

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

80% more funds holding

Funds holding: 10 [Q1] → 18 (+8) [Q2]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.41% less ownership

Funds ownership: 3.12% [Q1] → 2.71% (-0.41%) [Q2]

See Fund Rankings

Financial journalist opinion

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, announces CEO and Chairman Dr. Joseph Sinkule will attend the Inaugural Klotho Conference & Scientific Seminar.

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, provides a strategic update to shareholders highlighting the Company's key milestones and pipeline progress. These achievements strengthen Klotho's position as it advances toward the large and growing market for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Parkinson's disease therapies, which is estimated at over $8 billion annually by Grand View Research and others.

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. (AAVnerGene) platform technology. As previously announced, AAVnerGene is an innovation-driven biotech renowned for its transformative technologies in adeno-associated viruses (AAV) manufacturing and tissue-targeted delivery.

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Company to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK , July 25, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform.

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK , July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced today that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform.

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

NEW YORK , July 22, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven biotech renowned for its transformative technologies in AAV manufacturing and tissue-targeted delivery. Dr. Joseph Sinkule, the CEO of KLTO stated "we announced previously that we have been looking for a more efficient, 'next-generation' method to manufacture several of our patented gene therapy candidates, and the two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes.

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK , July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that it had received a notification letter from The NASDAQ Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under NASDAQ Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1). The Company is now in full compliance with all NASDAQ continued listing requirements and will remain listed and traded on the NASDAQ Stock Market.

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

Proactive Investors

Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation

Klotho Neurosciences (NASDAQ:KLTOW) announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan Drug Designation from the US Food and Drug Administration (FDA), The news sent Klotho's shares higher in early trade on Thursday, up 5.8% at about $1.45. ALS is a rare, progressive neurodegenerative disease commonly known as Lou Gehrig's disease.

Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

NEW YORK , July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or s-KL-AAV.myo) for the treatment of ALS. The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The Orphan Drug Designation provides certain incentives, such as tax credits, toward the cost of human clinical trials and a waiver for the payment of the GDUFA User Fee for market applications.

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

This Penny Stock Exploded 500% In June: What You Need To Know

Shares of the anti-aging biogenetics company Klotho Neurosciences, Inc. KLTO are on retail investors' radars after the stock exploded by more than 500% in June. Here's a look at recent catalysts that sent the stock soaring.

This Penny Stock Exploded 500% In June: What You Need To Know

See News Rankings

Charts implemented using Lightweight Charts™